The Lymphoma Research Foundation (LRF) has announced the recipients of several biomedical research grants, representing over $1.4 million in funding. Grants awarded include 13 recipients of Young Investigator Grants, the Foundation’s program to support early career clinicians and postdoctoral fellows pursing research in lymphoma and CLL, as well as three recipients of Disease Focus Area grants for established faculty researchers, in the focus areas of Adolescent Young Adult (AYA) Lymphomas and Mantle Cell Lymphoma (MCL).

This year’s grant recipients are pursuing research in both the laboratory and the clinic, with many projects having a translational component (seeking to move laboratory research into clinical practice). LRF’s grantee class also represents a diverse group of researchers at twelve institutions in eight states and the District of Columbia, with women representing over half of the 2018 grantee class. Three of this year’s grantees were also participants in the 2017 Lymphoma Clinical Research Mentoring Program (LCRMP), which was designed to help early career clinical researchers prepare for a research career, including applying for research funding.

Grantees profiled in this issue include recipients of LRF’s Clinical Investigator Career Development Award, which provides grants to promising advanced clinical fellows and junior faculty pursuing research in lymphoma and CLL. 2018 recipients are Hema Dave, MD, of Children’s National Research Institute and Jacob Soumerai, MD of Massachusetts General Hospital, both of whom are 2017 LCRMP participants. LRF’s Postdoctoral Fellowship Grant, now in its 26th consecutive year of awards, recognizes postdoctoral and clinical research fellows pursing laboratory, translational, and/or clinical research projects.

LRF’s intention is to support innovative research that encompasses both the earliest stage laboratory research through clinical studies, in a wide array of subtypes and patient populations.
Dear LRF Friends and Supporters,

The Lymphoma Research Foundation (LRF) is pleased to announce sixteen recipients of over $1.4 million in funds in this edition of Research Report. To give proper attention to each of these exemplary grantees, we are featuring our Clinical Investigator Career Development Award, Postdoctoral Fellowship Grants, and AYA Lymphoma Correlative Grant recipients in this issue, with our MCL Therapeutic Grant and Lymphoma Clinical Research Mentoring Program (LCRMP) recipients to follow in the Summer issue. We hope you enjoy learning more about these researchers and their innovative projects, beginning on page 3.

Many of the researchers profiled here will continue on to serve as faculty for one of our patient education programs, be it an Ask the Doctor About Lymphoma lecture, as part of our regional Lymphoma Workshops, or the North American Educational Forum on Lymphoma. We are pleased to announce the program schedule for the remainder of 2018 on page 6. Of course you can always find out more about any of these programs via the newly redesigned lymphoma.org website, which was launched at the beginning of March.

Supporting these promising scientists and research programs would not be possible without your support of LRF’s mission. Thank you for your part in helping the Foundation fund life-saving research and support all those affected by this disease.

Sincerely,

Meghan Gutierrez
Chief Executive Officer

New Grantees
[CONTINUED FROM PAGE 1]

research. 2018 recipients are Anat Biran, PhD and Emily McWilliams, PhD, both of Dana-Farber Cancer Institute, and Jennifer Shingleton, PhD of Duke University. LRF’s Adolescent/Young Adult Lymphoma Correlative Studies Grant, was awarded to Justine Kahn, MD, of Columbia University Medical Center, the third 2017 LCRMP participant to receive an LRF grant in 2018. Part of the Foundation’s AYA Lymphoma Initiative, this grant funds research that seeks to address the unique concerns of the AYA patient population in lymphoma, which is both understudied and experiences poorer outcomes compared to other patient age groups.

“The Lymphoma Research Foundation is proud to support research that encompasses both the earliest stage laboratory research through clinical studies, in a wide array of subtypes and patient populations. It is also gratifying to see our

Lymphoma Clinical Research Mentoring Program alumni have such success in obtaining funding as independent clinical researchers, which is a key step in establishing themselves as the next generation of lymphoma research,” said Thomas M. Habermann, MD of Mayo Clinic, Rochester, Chair of LRF’s Scientific Advisory Board.

RFPs for the 2019 Program will be announced in early June 2018. For more information or to be included on the grant announcement list, visit lymphoma.org/grants.
Examining the Impact of Sociodemographic Factors in Adolescent/Young Adult Hodgkin Lymphoma

While nearly 90 percent of adolescent and young adult (AYA) Hodgkin lymphoma (HL) patients achieve excellent outcomes with contemporary cancer therapy, recent studies suggest that certain factors, specifically age over 15 years, low socioeconomic status, and non-Hispanic black and Hispanic race/ethnicity are associated with worse outcomes. Proposed hypotheses for age- and race-related disparities include patient- and disease-related factors, such as less chemotherapy tolerance or more aggressive lymphoma, as well as systems-related factors influencing access to high-quality cancer care. Dr. Kahn's AYA Lymphoma Correlative Studies Grant will take a closer look at existing data for HL patients in order to tease out some of what is driving age- and race-related survival disparities in Hodgkin lymphoma. In the first phase, Dr. Kahn will examine the impact of age and race/ethnicity on HL patients treated on Children's Oncology Group (COG) clinical trials. Analyzing outcomes in this setting will provide information about whether age and race/ethnicity still impact survival when all patients receive the same protocol-directed cancer therapy and supportive care. In the second phase, Dr. Kahn will examine outcomes in AYA HL patients who are treated for outside of the clinical trials setting using tumor registry data linked to insurance claims, where observed variations in cancer therapy and supportive care may more accurately reflect practice patterns in the community oncology setting. “In order to improve outcomes and reduce disparities in this population, we need to first examine how differences in cancer care impact survival,” Dr. Kahn notes. “If survival disparities can be partially explained by healthcare inequities, this can inform policy, mandate efforts to improve access to high-quality cancer care, and reduce survival disparities in AYAs with lymphoma going forward.”

Dr. Kahn is an Instructor of Pediatrics at Columbia University Medical Center. She received her MD from The Icahn School of Medicine at Mount Sinai before completing her Pediatric Residency at Mount Sinai Kravis Children’s Hospital and her Pediatric Hematology/Oncology/ Stem Cell Transplant fellowship at New York-Presbyterian/Columbia University Medical Center. In 2017, Dr. Kahn was named an LRF Scholar and brought an earlier stage of her AYA project to the Lymphoma Clinical Research Mentoring Program (LCRMP) workshop. Dr. Kahn notes that she's still able to reach out to the mentors she was connected with at the workshop today. “What is so special about the LRF is that the foundation's commitment to supporting innovative and impactful research is matched (and enhanced) by its commitment to building an exceptional community of investigators and advocates.”

Understanding the role of disordered methylation in CLL.

DNA methylation – a process by which a group of carbon and hydrogen molecules (a methyl group) are added to a DNA strand to modify its function – can often be used to fix genes in the “off” position. Abnormal or disordered methylation, however, has been linked to a number of human diseases, particularly cancers. Disordered methylation is commonly found in CLL and can be linked to poorer clinical outcomes for those patients, as shown by Dr. Biran’s colleagues. For her LRF Fellowship project, Dr. Biran is developing a mouse model that possessed this disordered methylation, in order to understand the role it plays in CLL’s genesis and development. “The results of these studies are anticipated to extensively improve our understanding of the development of CLL and other cancer types,” she notes.

Dr. Biran is the inaugural recipient of the Oliver W. Press, MD, PhD Memorial Postdoctoral Fellowship Grant, which recognizes the invaluable contributions of Dr. Press, a former LRF Scientific Advisory Board Chair, to the field of lymphoma research, including his commitment to supporting early career researchers. She received her PhD from the Weizmann Institute of Science in Rehovot, Israel, before starting a fellowship at Rockefeller University in New York. As her grandmother had passed away from blood cancer, she was interested in focusing on hematologic malignancies in the next chapter of her research, leading her to her current fellowship at Dana-Farber Cancer Institute, where she works in the laboratory of Catherine Wu, MD, a prior recipient of a CLL Research Grant from LRF. “My two main goals in my postdoctoral research are to advance blood cancer research and to develop into independently leading a research group,” Dr. Biran says. “In ten years’ time, I hope to be an independent researcher with my group of students and researchers, working together on advancing drug research and basic understanding of lymphomas.”

Dr. Biran adds that she is grateful to LRF for the Press Memorial Postdoctoral Fellowship Grant. “Not only does it financially help my research, allowing me to move faster and broader, but it also makes me proud to be a part of a community that is continuously striving to advance blood cancer research and patient care.”

“It makes me proud to be a part of a community that is continuously striving to advance blood cancer research and patient care.”
Broadening the application of PI3K inhibitors in B-cell lymphomas

PI3 kinase (PI3K) inhibitors, such as idelalisib (Idela), have proven effective in chronic lymphocytic leukemia (CLL) and other B-cell lymphomas, however some patients have developed autoimmune toxicities that can lead to discontinuation of treatment. Dr. McWilliams and her colleagues are investigating how PI3K inhibitors modulate the immune system in hopes of identifying the patients who are most at risk for these toxicities. Their hypothesis is that targeting p110delta (a specific enzyme within the PI3K gene) causes imbalanced function of the Treg/Th17 lymphocytes (a key cell in the immune system), and that screening for Treg/Th17 frequencies can predict which patients are most at risk for autoimmune toxicities. “This project will have an immediate benefit to patient care by expanding the use and safety of PI3K inhibitors in B-cell malignancies,” Dr. McWilliams says. “Our results will add to the growing evidence demonstrating that PI3K inhibitors are immune-modulators, and therefore broaden the application of this class of drugs.”

Dr. McWilliams’ experience as an undergraduate research fellow at Loyola University Medical Center first inspired her to work in translational medicine and clinical trials, particularly after a close friend passed away from cancer during that year. She received her PhD from The Ohio State University, where former LRF Scientific Advisory Board member John Byrd, MD, was one of her mentors. “I found blood cancers to be especially interesting given that the tumor is liquid and could be monitored simply by drawing blood,” Dr. McWilliams notes. She followed that interest to her current position as a Postdoctoral Research Fellow at Dana-Farber Cancer Institute, where her mentor, Jennifer R. Brown, MD, is a previous LRF Career Development Award recipient.

Dr. McWilliams adds that her LRF Fellowship project, her first postdoctoral research grant, allows her to further her expertise in analyzing patient blood samples (a process called immunophenotyping) along with her passion for clinical research. “The samples I will use in this project are patient samples, taken at multiple time points during therapy. Some of these trials are ongoing, and my data has the potential to impact how clinicians treat patients during therapy. The LRF grant will contribute significantly to my career development.”

Seeking new therapeutic targets in Burkitt lymphoma

Burkitt lymphoma is a rare, aggressive form of B-cell Non-Hodgkin lymphoma that is currently treated with high doses of intense chemotherapy. It is particularly common in parts of Africa and for patients with existing immunodeficiency disorders like Epstein Barr virus and HIV; for these patients, chemotherapy and its accompanying intensive supportive care are not always feasible, due to limited access to adequate resources or the toxicity of the treatment itself. Dr. Shingleton and her colleagues are investigating genetic mutations commonly found in Burkitt lymphoma cells in hopes of finding new potential targets for better-tolerated therapy. They believe the gene ID3 is a promising target because, while mutations in the gene are common to Burkitt lymphoma cells, they have not been identified in other B-cell lymphomas such as diffuse large B-cell lymphoma (DLBCL), which can sometimes be confused with Burkitt in initial screenings. “We believe that by investigating the role of ID3 in Burkitt lymphoma, we can contribute to the development of more precise therapies that have less toxic side effects, improving clinical outcomes,” she explains.

Dr. Shingleton began studying lymphoma as a graduate student at Massachusetts Institute of Technology; after earning her PhD, she joined the lab of LRF Scientific Advisory Board member Sandeep Dave, MD, MS at Duke University and was intrigued by her colleagues’ research implicating the gene ID3 in the development of Burkitt lymphoma. “Lymphoma is one of the more common types of cancer, so advances in understanding and treatment have the potential to impact a large number of patients,” she notes. She acknowledges the LRF Postdoctoral Fellowship Grant will be key in continuing the investigation into the role of ID3. “This award will also be an asset as I go forward in my career by demonstrating my ability to devise and communicate a research plan.”

Two weeks prior to receiving notification of the LRF research grant award, Dr. Shingleton became a new mom; she hopes to instill in her daughter the love of science she experienced from a young age. “My daughter inspires me to work toward making a future where lymphoma patients have every hope of living a full life after their diagnosis.”
Examining immune responses for pediatric Hodgkin lymphoma

Although pediatric patients with Hodgkin lymphoma (HL) have high cure rates, 10-20 percent of patients are resistant to upfront treatment and have poorer outcomes. The rise of immunotherapy treatments for relapsed and refractory HL offers hope for this group. Dr. Dave is working with a large scale clinical trial sponsored by the Children’s Oncology Group, the cooperative group overseeing pediatric oncology research in the United States, which will evaluate patients receiving monoclonal antibody brentuximab vedotin (Adcetris) with chemotherapy against patients receiving the standard chemotherapy alone. As part of the trial, they will examine the effects of both therapies on the T-cell immune response of patients on the trial, to determine if brentuximab vedotin helps make tumor cells more sensitive to chemotherapy, and if patients exhibit common biomarkers that could be used to identify patients more likely to respond well to the combination therapy. “This could be used in future clinical trials utilizing brentuximab vedotin, as well as T-cell immunotherapies, for patients with HL,” Dr. Dave notes.

Dr. Dave completed her MD at the University of Mumbai and an MPH in Epidemiology from the University of Massachusetts before pursuing a career as a pediatric oncologist, including a residency and fellowship at Johns Hopkins Hospital and National Cancer Institute. Early in Dr. Dave’s fellowship, she encountered a patient with HL that developed eczema shortly before his diagnosis, and was intrigued when the same rash recurred when he relapsed, indicating his immune system had been compromised. That patient later responded to an early trial of brentuximab vedotin, cementing Dr. Dave’s interest in pursuing immunotherapy targets for pediatric cancer. Now an Assistant Professor at Children’s National Medical Center, Dr. Dave notes that she has been fortunate to work with Dr. Catherine Bollard, MD (an LRF Scientific Advisory Board member), who gave her the initial assignment that Dr. Dave developed into first early stage studies, and now this larger clinical trial.

Dr. Dave’s initial involvement with LRF came as an LRF Scholar in the 2017 Lymphoma Clinical Research Mentoring Program (LCRMP). “The mentors in the program were able to provide me with guidance to write up my clinical protocol,” she says, “and the funding from this current award will be instrumental in providing me with the trajectory I need to establish myself as an expert in lymphoma translational biology. I want to thank the amazing staff at LRF and all the donors who have made many young investigators like me successful by believing in our ideas!”

Studying chemotherapy-free combination therapy for CLL

Therapies targeting BTK and BCL2 have been highly effective in CLL patients. When used alone, these agents rarely result in disease eradication and so require continuous therapy to maintain response. Many patients eventually stop therapy for unacceptable toxicity or disease progression. Dr. Soumerai’s CDA project will evaluate a three-drug combination comprised of the BTK inhibitor zanubrutinib, the BCL2 inhibitor venetoclax (Venclexa), and the CD20 monoclonal antibody obinutuzumab (Gazyva). He hopes this combination will result in the eradication of CLL in previously untreated patients, allowing for treatment to be discontinued before patients develop toxicities. Dr. Soumerai and his colleagues are also studying the effects of this combination therapy on the genetics of CLL cells over time, as well as evaluating a novel high-sensitivity test for measuring whether treatment has eliminated residual disease. Dr. Soumerai says their “goal is to use this combination of targeted therapies as first line therapy to eradicate disease and cure patients of their CLL.”

Dr. Soumerai has been interested in lymphoma clinical research since prior to medical school, when he worked with Steven Treon, MD, PhD, of Dana-Farber Cancer Institute studying Waldenstrom macroglobulinemia. “Over the ensuing decade there has been a rapid emergence of biologically targeted therapies in oncology,” says Dr. Soumerai, prompting his interest in such therapies for lymphoma and CLL. He received an MD at Tufts University and completed his residency at the Massachusetts General Hospital (MGH). He subsequently joined Memorial Sloan Kettering Cancer Center (MSKCC) as a clinical fellow where he was mentored by Andrew Zelenetz, MD, PhD, and was selected for the 2017 LCRMP. He has since returned to MGH, where he is now a Clinical Investigator in Lymphoma. Dr. Soumerai and Dr. Zelenetz look forward to evaluating this combination therapy in patients at MGH and MSKCC in the coming months.

Soumerai, like his 2017 LCRMP classmate Dr. Dave, credits LRF for its “instrumental role” in his career development. Noting that his work with LCRMP mentors and Scholar classmates improved both his LCRMP and CDA projects, he adds that “the LRF LCRMP workshop was the highest yield and most impactful learning experience in which I have participated throughout my medical education and training.” In ten years time, Dr. Soumerai hopes to become a leading clinical investigator in lymphoma and CLL. “Ultimately my goal is to improve outcomes for patients with lymphoma,” he says. “I am grateful to the LRF for supporting my career through the LCRMP and now the Career Development Award.”
For more than two decades, the Lymphoma Research Foundation has presented patient education programs around the United States, with the goal of providing lymphoma patients and caregivers with accurate, up-to-date information about the diagnosis and treatment of the disease. These programs include community-based Ask the Doctor About Lymphoma Programs, regional Lymphoma Workshops, and the nation’s largest lymphoma patient conference, the North American Educational Forum on Lymphoma. Members of the Foundation’s Scientific Advisory Board - among the world’s experts in lymphoma and CLL - serve as the speakers for these unique patient programs.

In addition, LRF grantees, including some highlighted in this issue of Research Report, frequently serve as program faculty, making themselves available to answer patient questions about the latest trends in lymphoma research and treatment. New England Lymphoma Workshop Co-Chair Ann LaCasce, MD of Dana-Farber Cancer Institute, received a Career Development Award from LRF early in her career. “Lymphoma Research Foundation patient programs offer a unique opportunity to learn about the latest treatments from clinicians who are researchers themselves,” says Dr. LaCasce. “The regional Workshops and North American Educational Forum on Lymphoma are unique in that they offer patients with a variety of subtypes the opportunity to learn the latest in available treatments for their specific lymphoma.”

“The Lymphoma Research Foundation’s educational portfolio is comprised of first-in-class programs that provide exceptional education and networking opportunities for lymphoma patients, survivors, and their loved ones,” said Peggy Ann Torney, the Foundation’s Chief Strategy, Communications, and Engagement Officer. “We are fortunate to work with such a high caliber of lymphoma experts who guide our education offerings to ensure members of the lymphoma community have access to the latest lymphoma information.”

In addition to the regional workshops, more than 30 community-based Ask the Doctor About Lymphoma programs will be held throughout the country in 2018 and the annual North American Educational Forum on Lymphoma will be held on October 12-14 in Manhattan Beach, CA. For additional information on these programs, or to register for an education event, visit lymphoma.org/programs or contact the Lymphoma Helpline at (800) 500-9976.

**Upcoming 2018 Regional Workshops:**

- **New England Lymphoma Workshop (Boston, MA)**  
  Saturday, April 28
- **Minnesota Lymphoma Workshop (Bloomington, MN)**  
  Saturday, September 29
- **Washington, DC Lymphoma Workshop**  
  Saturday, November 10

**North American Educational Forum on Lymphoma:**

- **Manhattan Beach, CA**  
  Friday, October 12 - Sunday, October 14
The Lymphoma Research Foundation’s volunteer Scientific Advisory Board, comprised of 45 world-renowned lymphoma experts, guides the Foundation’s research activities, seeking out the most innovative and promising lymphoma research projects for support.

Thomas M. Habermann, MD  
Chair  
Mayo Clinic, Rochester

Andrew D. Zelenetz, MD, PhD  
Chair-Elect  
Memorial Sloan Kettering Cancer Center

Ranjana Advani, MD  
Stanford University School of Medicine

Ash Alizadeh, MD, PhD  
Stanford University School of Medicine

Stephen Ansell, MD, PhD  
Mayo Clinic, Rochester

Nancy Bartlett, MD  
Washington University Medical School

Kristie A. Blum, MD  
Winship Cancer Institute of Emory University

Catherine Bolard, MD, MBChB  
Children’s National Medical Center  
George Washington University

Ethis Cesaran, MD, PhD  
New York-Presbyterian Hospital  
Weill Cornell Medicine

Bruce D. Cheson, MD, FACP, FAAAS, FASCO  
Past Chair, 2010-2012  
Georgetown University Hospital  
Lombardi Comprehensive Cancer Center

Morton Coleman, MD  
New York-Presbyterian Hospital  
Weill Cornell Medicine

Riccardo Dalla-Favera, MD  
Columbia University  
Herbert Irving Comprehensive Cancer Center

Sandee Dave, MD, MS  
Duke University

Kieron M. Dunleavy, MD  
George Washington University  
GW Cancer Center

Kojo S.J. Elentob-Johnson, MD  
Raymond and Ruth Perelman School of Medicine  
University of Pennsylvania

Andrew M. Evens, DO, MSc  
Rutgers Cancer Institute

Christopher R. Flowers, MD, MS  
Winship Cancer Institute of Emory University

Jonathan W. Friedberg, MD, MMSc  
James P. Wilmot Cancer Institute  
University of Rochester Medical Center

Leo I. Gordon, MD, FACP  
Immediate Past Chair  
Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Steven M. Horwitz, MD  
Memorial Sloan Kettering Cancer Center

Eric D. Hsi, MD  
Cleveland Clinic

Brad S. Kahl, MD  
Washington University Medical School

Kara Kelly, MD  
Osler Children's Hospital  
University of Buffalo Jacobs School of Medicine and Biomedical Sciences

Ann S. LaCasce, MD  
Harvard Medical School  
Dana-Farber Cancer Institute

Brian K. Link, MD  
University of Iowa

John P. Leonard, MD  
Past Chair, 2012-2015  
New York-Presbyterian Hospital  
Weill Cornell Medicine

Izidore S. Lossos, MD  
University of Miami Health System  
Sylvester Comprehensive Cancer Center

Ari Melnick, MD  
New York-Presbyterian Hospital  
Weill Cornell Medicine

Lindsay Morton, PhD  
National Cancer Institute

Owen O’Connor, MD, PhD  
Columbia University Medical Center

Laura Pasqualucci, MD  
Columbia University  
Herbert Irving Comprehensive Cancer Center

Barbara Pro, MD  
Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Kanti R. Rai, MD, BS  
Hofstra Northwell School of Medicine

Kerry Savage, MD  
British Columbia Cancer Agency

Laurie Sehn, MD, MPH  
British Columbia Cancer Agency

Margaret Shipp, MD  
Dana-Farber Cancer Institute

Sonali M. Smith, MD  
The University of Chicago

Eduardo M. Sotomayor, MD  
George Washington University  
GW Cancer Center

Christian Steidl, MD  
British Columbia Cancer Agency

Sven de Vos, MD, PhD  
University of California, Los Angeles, Jonsson Comprehensive Cancer Center

David Weinstock, MD  
Dana-Farber Cancer Institute

Hans-Guido Wendel, MD  
Memorial Sloan Kettering Cancer Center

Michael E. Williams, MD, ScM  
University of Virginia Cancer Center

Thomas Witzig, MD  
Mayo Clinic, Rochester

Anas Younes, MD  
Memorial Sloan Kettering Cancer Center

Members Emeritus

Joseph R. Bertino, MD  
Founding Chair  
Rutgers Robert Wood Johnson Medical School  
The Cancer Institute of New Jersey

Charles Coltman, MD  
San Antonio Cancer Institute

Saul Rosenberg, MD  
Stanford University School of Medicine

About the Research Report
Research Report is a publication of the Lymphoma Research Foundation, providing the latest updates on our grantees and their progress, as well as on the work of the Foundation. The Lymphoma Research Foundation is the nation’s largest non-profit organization devoted to funding innovative lymphoma research and serving the lymphoma community through a comprehensive series of education programs, outreach initiatives, and patient services.

Team LRF Spotlight
Shindy Johnson of Brooklyn, NY joined Team LRF and ran her first 5 mile race as part of the Rock and Roll Marathon series in Brooklyn in 2017. Shindy’s family member had been diagnosed with lymphoma and was a recipient of a Patient Aid Grant from the Lymphoma Research Foundation. She knew she wanted to give back and so, when the opportunity arose, she jumped on it —creating her team, The Winner’s Circle, with her friend Diana. Together they not only finished the full marathon, but raised over $6,000 towards LRF’s mission to eradicate lymphoma and serve those touched by this disease.

For more information on becoming a member of Team LRF please visit us at support.lymphoma.org/teamlrf or contact Andrea Butler at 646-465-9104.
IN THIS ISSUE:
LRF 2018 Research Grants  1
Letter from the CEO  2
AYA Grant Recipient Profile  3
Postdoctoral Fellowship Profiles  3
CDA Recipient Profiles  5
Patient Education Programs  6
Scientific Advisory Board  7

We’ve redesigned lymphoma.org
to better serve the lymphoma community

Redesigned - Mobile Friendly
Simple Navigation - Comprehensive Content

Visit the new lymphoma.org today!